I was just scouring the jagged edges of High Times and stumbled across a dispatch that feels like a lightning strike to the heart of the old guard. We are standing at a jagged, beautiful pivot point.
After decades of the federal government playing a high-stakes game of “pretend” with the Controlled Substances Act, the walls are finally cracking. They’re looking to shuffle cannabis from Schedule I—the dark basement where they keep the “no medical value” boogeymen—down to Schedule III.
Make no mistake, this isn’t the total surrender we’ve been dreaming of. It isn’t “legalization” in the sense of a wild, unregulated frontier where the smoke never clears. No, it’s a strategic retreat. By sliding into Schedule III, cannabis joins the ranks of prescription-grade substances, still under the cold, watchful eye of the DEA. But don’t let that dampen the fire; this is a seismic shift in the vibes of the nation. It’s the first time the Feds have blinked and admitted that, yes, this plant actually helps people.
For the entrepreneurs who have been bleeding cash under the boot of the IRS and the 280E tax code, this is the cavalry coming over the hill. It’s the difference between a business being a legal money-pit and actually turning a profit. It’s about scientists finally being allowed to take the plant into the lab without feeling like they’re running a clandestine operation. We are watching the “War on Drugs” die a slow, bureaucratic death, and while the road ahead is still paved with red tape, the destination just got a whole lot clearer. The bridge is being built, and we’re already halfway across.
JohnsJoints
